Fundz
Real-time · AI · Cross-signal

Vor Bio just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Vor Bio, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Vor Bio Announces $55.6 Million Private Placement with New Investor Reid Hoffman

Dec 27, 2024•over 1 year ago

Contract Type

partnership

CambridgeBiotechnologyHealth CareTherapeutics

Description

Vor Bio announced a private investment in public equity financing (PIPE) that is expected to result in gross proceeds of approximately $55.6 million. The investment was led by new investor Reid Hoffman and included participation from existing investor RA Capital Management. As part of the investment, Mr. Hoffman and RA Capital Management are being granted one board seat and one board observer seat.

Company Information

Company

Vor Bio

Location

Cambridge, Massachusetts, United States

About

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Vor Bio's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months